Dr. Mark A. Sherman has studied antibody structure and function for over 20 years. His expertise lies in antibody modeling, engineering and humanization. He played a key role in the humanization of T84.66 and 1G8, antibodies used in radioimmunotherapy to detect and treat colon and prostate cancer. Both are currently undergoing clinical trials.

Link to PubMed search results for publications by this author.